Proto-oncogenes regulate cell growth; mutations convert them to oncogenes, leading to cancer by disrupting normal cell ...

历经多年不懈探索，奥希替尼在 EGFR 突变 NSCLC 治疗领域不断突破，至今已 8 次荣登 NEJM，成为其传奇历程的见证。与此同时，奥希替尼的应用范围不断扩大，从晚期扩展到早期，从后线治疗走向前线治疗，从单药治疗到联合治疗，其在国内已有 4 个适应症获批上市，是目前国内适应症范围最广*的 EGFR-TKI。而且，奥希替尼是目前唯一*的一线、二线及辅助治疗适应症均纳入医保的三代 ...

Findings showed treatment with Rybrevant plus chemotherapy significantly reduced the risk of disease progression or death by 52% compared with chemotherapy.

ArriVent BioPharma is developing a treatment for non-small cell lung cancer. Click here to read more about AVBP stock and ...

The FDA approval of amivantamab-vmjw (Rybrevant) in combination with chemotherapy is the first targeted treatment to cut ...

Approvals are coming fast and furious for Johnson & Johnson’s Rybrevant as it is lining up to challenge the dominance of ...

Johnson & Johnson (JNJ) announced that the U.S. Food and Drug Administration approved RYBREVANT (amivantamab-vmjw) in combination ...

Black women in the US have a significantly higher risk of breast cancer mortality across all subtypes, with disparities ...

Wednesday announced the receipt of Fast Track Designation from the FDA for ATR-04, a topical treatment targeting ...

The epidermal growth factor receptor tyrosine kinase inhibitor aumolertinib demonstrated improved progression-free survival ...

Some patients with non-small cell lung cancer (NSCLC) have mutations in a gene called human epidermal growth factor receptor ...